These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34749590)

  • 1. Mutated JAK2 signal transduction in human induced pluripotent stem cell (iPSC)-derived megakaryocytes.
    Pawinwongchai J; Jangprasert P; Nilsri N; Israsena N; Rojnuckarin P
    Platelets; 2022 Jul; 33(5):700-708. PubMed ID: 34749590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.
    Nilsri N; Jangprasert P; Pawinwongchai J; Israsena N; Rojnuckarin P
    Sci Rep; 2021 Mar; 11(1):5255. PubMed ID: 33664283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.
    Flosdorf N; Böhnke J; de Toledo MAS; Lutterbach N; Lerma VG; Graßhoff M; Olschok K; Gupta S; Tharmapalan V; Schmitz S; Götz K; Schüler HM; Maurer A; Sontag S; Küstermann C; Seré K; Wagner W; Costa IG; Brümmendorf TH; Koschmieder S; Chatain N; Castilho M; Schneider RK; Zenke M
    Stem Cell Reports; 2024 Feb; 19(2):224-238. PubMed ID: 38278152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
    Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
    Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
    Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
    Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
    Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.
    Chen E; Beer PA; Godfrey AL; Ortmann CA; Li J; Costa-Pereira AP; Ingle CE; Dermitzakis ET; Campbell PJ; Green AR
    Cancer Cell; 2010 Nov; 18(5):524-35. PubMed ID: 21074499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
    Grimwade LF; Happerfield L; Tristram C; McIntosh G; Rees M; Bench AJ; Boyd EM; Hall M; Quinn A; Piggott N; Scorer P; Scott MA; Erber WN
    Br J Haematol; 2009 Nov; 147(4):495-506. PubMed ID: 19747364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
    Schnittger S; Bacher U; Haferlach C; Geer T; Müller P; Mittermüller J; Petrides P; Schlag R; Sandner R; Selbach J; Slawik HR; Tessen HW; Wehmeyer J; Kern W; Haferlach T
    Haematologica; 2009 Mar; 94(3):414-8. PubMed ID: 19252176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
    Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
    Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.
    Schwemmers S; Will B; Waller CF; Abdulkarim K; Johansson P; Andreasson B; Pahl HL
    Exp Hematol; 2007 Nov; 35(11):1695-703. PubMed ID: 17764814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia.
    Kapralova K; Horvathova M; Pecquet C; Fialova Kucerova J; Pospisilova D; Leroy E; Kralova B; Milosevic Feenstra JD; Schischlik F; Kralovics R; Constantinescu SN; Divoky V
    Blood; 2016 Sep; 128(10):1418-23. PubMed ID: 27389715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.
    Li J; Kent DG; Godfrey AL; Manning H; Nangalia J; Aziz A; Chen E; Saeb-Parsy K; Fink J; Sneade R; Hamilton TL; Pask DC; Silber Y; Zhao X; Ghevaert C; Liu P; Green AR
    Blood; 2014 May; 123(20):3139-51. PubMed ID: 24692758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
    Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
    Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.